March 21-23, 2017 | Boston, MA

Thank you to everybody involved in ICI Boston this year. Over three content-packed days, leaders from throughout the field gathered to learn from insightful talks and engage in productive discussions around the key topics driving the industry forward.

The main conference program incorporated over 30 presentations from some of the leaders in the field. Three particular highlights of the program were:

  • Bristol-Myers Squibb discussed solutions to overcome key immuno-oncology challenges, including utilizing novel endpoints, optimizing collaboration strategies and bringing in next generation drug labelling approaches
  • Merck shared comprehensive insights into their pembrolizumab program, including discussions around PD-L1 expression and the mutational landscape as part of the next generation of biomarker strategies.
  • The FDA gave an invaluable regulatory perspective, dissecting approvals in the immune checkpoint inhibitor space before going on to discuss regulatory considerations in development programs including trial design and endpoints, biomarker strategies and safety issues.

We are already busy building next year’s program. If you are interested in partnering, speaking or attending ICI Boston next year simply register your interest and we’ll be in touch.

“Excellent meeting. Great opportunity for discussions between academia, small start ups, large pharma and regulatory authorities.” Merck

Beacon button
ICI vid thumb